Prognostic Significance of Tumour Markers in Endometrial Cancer

Lo, Stephen T.H.; Cheng, Danny; Ng, TY; Wong, L.C.; Ngan, Hextan Y.S.

doi:10.1159/000218037

Cited by 45 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies have investigated biomarkers for endometrial cancer [1][2][3][4][5][6] . In particular, measurement of cancer antigen 125 (CA125) in serum has been investigated as a tumour marker in patients with endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Carcinoembryonic Antigen as a Tumour Marker in Patients with Endometrial Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although several biomarkers have been associated with clinical characteristics and prognosis in endometrial cancer [1][2][3][4][5][6] , none have been implemented in clinical practice. Novel biomarkers for endometrial cancer are therefore required.…”

Section: Introductionmentioning

confidence: 99%

Serum Carcinoembryonic Antigen as a Tumour Marker in Patients with Endometrial Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For example, p53, hypoxia-inducible factor 1α (HIF-1α, HIF-2α), Ki-67, VEGF, EGFR, and HER2/neu correlate with development or progression of endometrial cancer [5]. Elevated levels of CA 125, CA 15-3 and CA 19-9 are significantly associated with shorter survival time in endometrial cancer patients [6]. CA 125 correlates with tumor size and stage of endometrial cancer [7][8][9] and is also a significant independent predictor of the extrauterine spread of disease [10].…”

Section: Introductionmentioning

confidence: 99%

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

Yurkovetsky

Ta’asan

Skates

et al. 2007

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Endometrial carcinoma is the most common gynecologic cancer. Although the prognosis for endometrial cancer is generally good, cancers identified at late stages are associated with high levels of morbidity and mortality. Therefore, prevention and early detection may further reduce the burden of this challenging disease.Methods-A panel of 64 serum biomarkers was analyzed in sera of patients with stages I-III endometrial cancer and age-matched healthy women, utilizing a multiplex xMAP ™ bead-based immunoassay. For multivariate analysis, four different statistical classification methods were used: logistic regression (LR), separating hyperplane (SHP), k nearest neighbors (KNN), and Classification Tree (CART). For each of these classifiers a diagnostic model was created, based on the crossvalidation set consisting of sera from 115 patients with endometrial cancer and 135 healthy women.Results-Our data have demonstrated that patients with endometrial cancer have significantly different expression patterns of several serum biomarkers as compared to healthy controls. Prolactin was the strongest discriminative biomarker for endometrial cancer providing 98.3% sensitivity and 98.0% specificity alone. Our results have revealed that serum concentration of cancer antigens, including CA 125, CA 15-3, and CEA are higher in patients with Stage III endometrial cancer as compared to those with Stage I. In addition, we have shown that the expression of CA 125, AFP and ACTH is elevated in women with tumor grade 3 vs. grade 1. Furthermore, 5-biomarker panel Requests for reprints: Anna Lokshin, University of Pittsburgh Cancer Institute, Hillman Cancer Center, 5117 Centre Ave., Pittsburgh, PA 15213. Phone: 412-623-7706; Fax: 412-623-1415; E-mail: lokshina@pitt.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. (prolactin, GH, Eotaxin, E-selectin, and TSH) identified in this study, was able to discriminate endometrial cancer from ovarian and breast cancers with high sensitivity and specificity. NIH Public AccessConclusions-The ability of prolactin to accurately discriminate between cancer and control groups indicates that this biomarker could potentially be used for development of blood-based test for the early detection of endometrial cancer in high-risk populations. Combining the information on multiple serum markers using flexible statistical methods allows for achieving high cancer selectivity.

show abstract

“…Elevated pretreatment serum CA 125 levels are often associated with a poor clinical outcome [26]. Scambia et al found a statistically significant relationship between CA 125 > 65 U/ml and a shorter survival [14].…”

Section: Ca 125mentioning

confidence: 99%

The Value of Tumor Markers in Endometrial Carcinoma: Review of Literature

Yaşa¹,

Takmaz²,

Dural³

et al. 2013

JCT

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecologic malignancy in more developed countries. Most endometrial carcinomas cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15% -20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. Although it has a comparatively low mortality rate compared with other gynaecological cancers, it is capable of aggressive behaviour. Diagnosis at an early stage is the most important determinant of survival. Discovery of new diagnostic biomarkers/panels for early diagnosis of endometrial cancer is one of the main challenges of modern medicine. For endometrial cancers, there are no established serum markers. We will review the present knowledge regarding tumor markers, assessing how such markers could be applied to address in screening, diagnosis and monitoring of endometrial carcinoma.

show abstract

Prognostic Significance of Tumour Markers in Endometrial Cancer

Cited by 45 publications

References 10 publications

Serum Carcinoembryonic Antigen as a Tumour Marker in Patients with Endometrial Cancer

Serum Carcinoembryonic Antigen as a Tumour Marker in Patients with Endometrial Cancer

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

The Value of Tumor Markers in Endometrial Carcinoma: Review of Literature

Contact Info

Product

Resources

About